Raxatrigine
Author: Sultan Khan
Publisher: Datamonitor Healthcare
- Description
- Companies
- Contents
- Enquire
Drug Overview
Raxatrigine (Biogen) is a peripherally and centrally acting agent that inhibits sodium channels in a state-dependent fashion. Raxatrigine shows selectivity for the Nav1.7 subtype over the other subtypes. Nav1.7, which is expressed in most dorsal root ganglion neurons, has been demonstrated to transmit action potentials generated by noxious stimuli. This has been confirmed as loss-of-function mutations in the SCN9A gene encoding Nav1.7 channels cause congenital insensitivity to pain in both humans and mice. Deletion of Nav1.7 is believed to result in upregulation of enkephalin precursor Penk mRNA and met-enkephalin protein within sensory neurons, resulting in increased production of endogenous opioids. This suggests that raxatrigine may present a synergistic effect with exogenous opioids
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 raxatrigine : Neuropathic pain
LIST OF FIGURES
9 Figure 1: Raxatrigine for neuropathic pain – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of raxatrigine for neuropathic pain
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of raxatrigine for neuropathic pain
13 Figure 4: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
LIST OF TABLES
6 Table 1: Raxatrigine drug profile
7 Table 2: Raxatrigine Phase II data in neuropathic pain
8 Table 3: Raxatrigine Phase III trials in neuropathic pain
14 Table 4: Raxatrigine sales for neuropathic pain across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the